𝔖 Bobbio Scriptorium
✦   LIBER   ✦

25 LONG TERM – 8 YEAR FOLLOW UP OF A RANDOMIZED TRIAL OF TACROLIMUS MONOTHERAPY VERSUS TRIPLE THERAPY AFTER LIVER TRANSPLANTATION FOR HCV CIRRHOSIS

✍ Scribed by Manousou, P.; Samonakis, D.; Tsochatzis, E.; Cholongitas, E.; Davidson, J.; Patch, D.; Rolles, K.; Hall, A.; Hayes, P.; McCormick, A.; Dhillon, A.P.; Burroughs, A.K.

Book ID
122590834
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
53 KB
Volume
58
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outcome of recurrent hepatitis C virus a
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy
✍ Pinelopi Manousou; Dimitrios Samonakis; Evangelos Cholongitas; David Patch; Jame 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

Less potent immunosuppression is considered to reduce the severity of hepatitis C virus (HCV) recurrence after liver transplantation. An optimal regimen is unknown. We evaluated tacrolimus monotherapy versus triple therapy in a randomized trial of 103 first transplants for HCV cirrhosis. One hundred

Reply: Outcome of recurrent hepatitis C
Reply: Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy
✍ Dinesh Jothimani; Timothy J. S. Cross 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB 👁 1 views

We read with interest the article by Manousou and colleagues, 1 investigating the impact of tacrolimus monotherapy (MT) versus triple therapy (TT) on recurrent hepatitis C infection after liver transplantation. This study examined hepatic fibrosis progression in patients randomized to tacrolimus MT